FDA expands use of Allergan's Botox to include overactive bladder

01/20/2013 | Reuters · MedPage Today (free registration)

Allergan's Botox, or onabotulinumtoxin A, has been approved by the FDA for use in patients with overactive bladder who can't take or don't improve with anticholinergics. The approval was based on results of two clinical studies showing that Botox reduced the frequency of incontinence and urination compared with placebo.

View Full Article in:

Reuters · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC